Prospects of molecularly-targeted therapies for cervical cancer treatment

Current Drug Targets

Volumn 16, Issue 1, 2015, Pages 77-91

  de Freitas, Antonio Carlos ^a   Leitão, Maria da Conceição Gomes ^a   Coimbra, Eliane Campos ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cervical cancer; HPV; microRNA; Molecular targets; Therapy

Indexed keywords

3, 3' DIINDOLYLMETHANE; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GLYCOPROTEIN E1; GLYCOPROTEIN E2; MICRORNA; MICRORNA 101; MICRORNA 143; MICRORNA 181A; MICRORNA 203; MICRORNA 21; MICRORNA 218; MICRORNA 29A; MICRORNA 34A; MICRORNA 424; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN E5; PROTEIN E6; PROTEIN E7; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIRUS DNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; DNA INTEGRATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; LIFE CYCLE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS; ALPHAPAPILLOMAVIRUS; DEVELOPED COUNTRY; DRUG EFFECTS; FEMALE; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ALPHAPAPILLOMAVIRUS; DEVELOPED COUNTRIES; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84922294150     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666141205150942     Document Type: Article

References (225)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44.
2. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378: 1461-84.
3. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
5. Bosh FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 1: 3-13.
6. Munoz N, Castellsague X, de Gonzalez AB, Gissmanl L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; S3: 1-10.
7. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-9.
8. Derchain SFM, Longatto Filho A, Syrjanen KJ. Neoplasia intraepitelial cervical: diagnóstico e tratamento. Rev Bras Ginecol Obstet 2005; 27425-433.
9. Pinto AP, Degen M, Villa LL, Cibas ES. Immunomarkers in gynecologic cytology: the search for the ideal biomolecular papanicolaou test. Acta Cytol 2012; 56: 109-121.
10. Merck & Co Inc. GARDASIL, Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Suspension for intramuscular injection 2006.
11. GlaxoSmithKline UK. Cervarix suspension for injection in prefilled syringe Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 2007.
12. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT. Mechanisms of human papillomavirus type 16 neutralization by L2 crossneutralizing and L1 type-specific antibodies. J Virol 2008; 82: 4638-4646.
13. Kling M, Zeichner JA. The role of the human papillomavirus (HPV) vaccine in developing countries. Int J Dermatol 2010; 49: 377-379.
14. Freitas AC, Mariz FC, Coimbra EC, Cordeiro MN, Jesus ALS. Vaccine Strategies against Human Papillomavirus: A Discussion Focused on Developing Countries. J Clin Cell Immunol 2012; S4: 004.
15. Provansal M, Cappiello M, Rousseau F, Goncalves A, Viens P. In: Topics on Cervical Cancer With an Advocacy for Prevention; New Therapeutic Targets, Ed. Rajamanickam Rajkumar: InTech 2012.
16. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immuneresponse modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230-9.
17. Greenfield I, Cuthill S. Antivirals. In: Sexually Transmitted Infections; Human papillomaviruses. Clinical and scientific advances, Ed. Sterling JC, Tyring SK: London 2001; Vol. 78: pp 120-30.
18. Bernard HU. Established and potential strategies against papillomavirus infections. J Antimicrob Chemother 2004; 53: 137-9.
19. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000; 79: 294-9.
20. Costa S, De Simone P, Venturoli S, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 2003; 90: 358-65.
21. Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol 2012; 126: 304-11.
22. Yavas G, Yavas C. Comment on 'Quality of life and emotional distress in early stage and locally advanced cervical cancer pa tients: a prospective, longitudinal study' by Ferrandina et al. Gynecol Oncol 2012; 124: 389-94.
23. Peralta-Zaragoza O, Bermúdez-Morales VH, Madrid-Marina V. Targeted treatments for cervical cancer: a review. Onco Targets Ther 2012; 5: 315-28.
24. D'Abramo CM, Archambault J. Small molecule inhibitors of human papillomavirus protein-protein interactions. Open Virol J 2011; 5: 80-95.
25. Freitas AC, Coimbra EC, Leitão MD. Molecular targets of HPV oncoproteins: Potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta 2014; 1845: 91-103.
26. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32: 7-15.
27. Favre M, Ramoz N, Orth G. Human papillomaviruses: general features. Clin Dermatol 1997; 15: 181-98.
28. Frattini MG, Laimins, LA. Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proc Natl Acad Sci 1994; 91: 12398-402.
29. de Prat-Gay G, Gaston K, Cicero DO. The papillomavirus E2 DNA binding domain. Front Biosci 2008; 13: 6006-21.
30. Benson JD, Lawande R, Howley PM. Conserved interaction of the papillomavirus E2 transcriptional activator proteins with human and yeast TFIIB proteins. J Virol 1997; 71: 8041-7.
31. Lee D, Lee B, Kim J, Kim DW, Choe J. cAMP response elementbinding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J Biol Chem 2000; 275: 7045-51.
32. Muller A, Ritzkowsky A, Steger G. Cooperative activation of human papillomavirus type 8 gene expression by the E2 protein and the cellular coactivator p300. J Virol 2002; 76: 11042-53.
33. Ilves I, Kivi S, Ustav M. Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which Is mediated by the viral E2 protein and its binding sites. J Virol 1999; 73: 4404-12.
34. Hegde RS. The papillomavirus E2 proteins: structure, function, and biology. Annu Rev Biophys Biomol Struct 2002; 31: 343-60.
35. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-60.
36. Venuti A, Paolini F, Nasir L, et al. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011; 10: 140.
37. McLaughlin-Drubin ME, Münger K. Oncogenic activities of human papillomaviruses. Virus Res 2009; 143: 195-208.
38. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
39. Howley PM, Scheffner M, Munger K. Oncoproteins encoded by the cancerassociated papillomavirus target the products of retinoblastoma and p53 tumor suppressor genes. Quant Biol 1991; 56: 149-55.
40. Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Cancer Biology 1999; 9: 379-86.
41. Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. The Faseb Journal 1993; 7: 872-79.
42. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002; 16: 245-56.
43. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
44. Kruse AJ, Baak JP, de Bruin PC, et al. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol 2001; 193: 48-54.
45. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-48.
46. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
47. Baldwin P, Laskey R, Coleman N. Translational approaches to improving cervical screening. Nat Rev Cancer 2003; 3: 217-26.
48. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005; 331: 269-91.
49. Motoyama S, Ladnines-Llave CA, Villanueva SL, Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci 2004; 50: 9-19.
50. Ueda Y, Enomoto T, Miyatake T, et al. Monoclonal expansion with integration of high-risk type human papillomaviruses is an initial step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab Investig 2003; 83: 1517-27.
51. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995; 69: 2989-97.
52. Dimaio D, Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 2001; 20: 7866-73.
53. Kristiansen E, Jenkins A, Holm R. Coexistence of episomal and integrated HPV16 DNA in squamous cell carcinoma of the cervix. J Clin Pathol 1994; 47: 253-6.
54. Arias-Pulido H, Peyton CL, Joste NE, Vargas, H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 2006; 44: 1755-62.
55. Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH, Chen SL. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci 2001; 8: 206-13.
56. Maufort JP, Shai A, Pitot HC, Lambert PF. A role for HPV16 E5 in cervical carcinogenesis. Cancer Research 2010; 70: 2924-31.
57. Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. Journal of Virology 1995; 69: 3185-92.
58. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-66.
59. Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor MEK/ERK1, 2 and PI3K/Akt. Cell Mol Life Sci 2006; 63: 930-38.
60. Tsao YP, Li LY, Tsai TC, Chen SL. Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratino-cytes. J Virol 1996; 70: 7535-39.
61. Pedroza-Saavedra EW, Lam F, Esquivel-Guadarrama F, Gutierrez-Xicotencatl L. The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1), Virology 2010; 400: 44-52.
62. Venuti A, Salani D, Poggiali F, Manni V, Bagnato A. The E5 oncoprotein of human papillomavirus type 16 enhances endothelin-1-induced keratinocyte growth. Virology 1998; 248: 1-5.
63. Chell SD, Witherden IR, Dobson RR, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Research 2006; 66: 3106-13.
64. Oh JM, Kim SH, Lee YI, et al. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 2009; 30: 141-9.
65. Kim SH, Oh JM, No JH, Bang YJ, Juhnn YS, Song YS. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009; 30: 753-7.
66. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-86.
67. Huang M, Chen Q, Xiao J, Liu C, Zhao X. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer 2013; 132: 363-73.
68. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev 2005; 15: 410-15.
69. Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J Mol Biol 2013; 425: 3582-600.
70. Lajer CB, Garnæs E, Friis-Hansen L, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 2012; 106: 1526-34.
71. Reshmi G, Radhakrishna Pillai M. in: Interplay Between HPV Oncoproteins and MicroRNAs in Cervical Cancer; Human Papillomavirus and Related Diseases-From Bench to Bedside, Ed. Dr. Davy Vanden Broeck: InTech 2012.
72. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
73. Greco N, Kivi K, Qian SK, Leivonen P, Auvinen E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 2011; 6: e21646.
74. Zheng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011; 1809: 668-77.
75. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-34.
76. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-43.
77. Melar-New M, Laimins A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 2010; 84: 5212-21.
78. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012; 12: 14.
79. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
80. Vici P, Mariani L, Pizzuti L, et al. Emerging Biological Treatments for Uterine Cervical Carcinoma. J Cancer 2014; 5: 86-97e.
81. Goncalves A, Fabbro M, Lhommé C, et al. A phase II trial to evaluate gefitinib as second-or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008; 108: 42-6.
82. Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009; 19: 929-33.
83. Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122: 495-500.
84. Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184. Gynecol Oncol 2010; 116: 163-67.
85. Schefter TE, Winter K, Kwon JS et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys 2012; 83: 1179-84.
86. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013; 130: 64-8.
87. Ferrandina G, Ranelletti FO, Legge F, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res 2003; 9: 4324-31.
88. Herrera FG, Chan P, Doll C, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 2007; 67: 97-103.
89. Doll CM, Winter K, Gaffney DK, et al. COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. Int J Gynecol Cancer 2013; 23: 176-83.
90. White PW, Faucher AM, Goudreau N. Small molecule inhibitors of the human papillomavirus e1-e2 interaction. Curr Top Microbiol Immunol 2011; 348: 61-88.
91. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus positive cancer cells. Oncogene 2003; 22: 5938-45.
92. Sima N, Wang S, Wang W, et al. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 2007; 106: 299-304.
93. Alvarez-Salas LM, DiPaolo JA. Molecular approaches to cervical cancer therapy. Curr Drug Discov Technol 2007; 4: 208-19.
94. Alvarez-Salas LM. Nucleic acids as therapeutic agents. Curr Top Med Chem 2008; 85: 1379-404.
95. Pushpendra S, Arvind P, Anil B. In: Nucleic Acids as Therapeutics Gene therapy; From Nucleic Acids Sequences to Molecular Medicine RNA Technologies, Ed. V. A. Erdmann and J. Barciszewski: Springer-Verlag Berlin Heidelberg 2012, pp. 20-45.
96. Hall AH, Alexander KA. RNA Interference of Human Papillomavirus Type 18 E6 and E7 Induces Senescence in HeLa Cells. J Virol 2003; 77: 6066-9.
97. Hengstermann A, D'silva MA, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M. Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol 2005; 79: 9296-300.
98. Yamato K, Fen J, Kobuchi H. Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther 2006; 13: 234-41.
99. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
100. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
101. Wang V, Wu W. MicroRNA-based therapeutics for cancer. Bio-Drugs 2009; 23: 15-23.
102. Bhardwaj A, Singh S, Singh AP. MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol 2010; 2: 213-219.
103. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
104. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000; 6(3): 747-53.
105. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother. 2003 May; 52(5): 342-6. Epub 2003 Mar 14.
106. Nogueira-Rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer 2014; 120: 1187-93.
107. Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol 2009; 113: 16-20.
108. Hertlein L, Lenhard M, Kirschenhofer A, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011; 283: 109-13.
109. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
110. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
111. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734-43.
112. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013; 130: 64-8.
113. Schefter T, Winter K, Kwon JS, et al. Int J RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Radiat Oncol Biol Phys 2014; 88: 101-5.
114. Elit LM, Hirte H. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert Rev Anticancer Ther 2014; 14: 319-32.
115. Farley JH, Truong V, Goo E, Uyehara C, Belnap C, Larsen WI. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia. Gynecol Oncol 2006; 103: 425-30.
116. Hefler LA, Grimm C, Speiser P, Sliutz G, Reinthaller A. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. Eur J Obstet Gynecol Reprod Biol 2006; 125: 251-4.
117. Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 2008; 109: 140-5.
118. Grabosch SM, Shariff OM, Wulff JL, Helm CW. Non-steroidal anti-inflammatory agents to induce regression and prevent the pro gression of cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2014; 4: CD004121.
119. Saldivar JS, Lopez D, Feldman RA. COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study. Gynecol Oncol 2007; 107: S155-S162.
120. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
121. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921-29.
122. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-62.
123. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-37.
124. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
125. Zhang XY, Zhang HY, Zhang PN, Lu X, Sun H. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008; 139: 237-44.
126. Errihani H, M'Rabti H, Ismaili N, Inrhaoun H, Elghissassi I. Phase II trial of capecitabine and cisplatin in advanced; persistent; or recurrent carcinoma of the cervix. Int J Gynecol Cancer 2011, 21: 373-77.
127. Castanon A, Tristram A, Mesher D, et al. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities, Double-blind; randomised; controlled trial. Br J Cancer 2012; 106: 45-52.
128. Zhu J, Li Y, Guan C, Chen Z. Anti-proliferative and proapoptotic effects of 3, 3'-diindolylmethane in human cervical cancer cells. Oncol Rep 2012; 28: 1063-68.
129. Ji J, Zheng PS. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 2010; 117: 103-8.
130. Chi EY, Viriyapak B, Kwack HS, et al. Regulation of paclitaxelinduced programmed cell death by autophagic induction: A model for cervical cancer. Obstet Gynecol Sci 2013; 56: 84-92.
131. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010; 117: 473-6.
132. Tinker AV, Ellard S, Welch S, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol 2013; 130: 269-74.
133. Wu J, Chen C, Zhao KN. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer. Curr Cancer Drug Targets 2013; 13: 143-56.
134. Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol 2005; 96: 168-72.
135. Martínez-Monge R, Gaztañaga M, Aramendía JM. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer. Int J Gynecol Cancer 2010; 20: 133-40.
136. Lorusso D, Ramondino S, Mancini M, Zanaboni F, Ditto A, Raspagliesi F. Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combination as Neoadjuvant Chemotherapy for Locally Advanced Cervical Adenocarcinoma. Int J Gynecol Cancer 2014; 24: 729-34.
137. Steger G, Ham J, Lefebvre O, Yaniv M. The bovine papillomavirus 1 E2 protein contains two activation domains: one that interacts with TBP and another that functions after TBP binding. EMBO J 1995; 14: 329-40.
138. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology 2009; 384: 375-9.
139. Sanders CM, Stenlund A. Recruitment and loading of the E1 initiator protein: an ATP-dependent process catalysed by a transcription factor. EMBO J 1998; 17: 7044-55.
140. White PW, Pelletier A, Brault K, et al. Characterization of recombinant HPV6 and 11 E1 helicases: effect of ATP on the interaction of E1 with E2 and mapping of a minimal helicase domain. J Biol Chem 2001; 276: 22426-38.
141. Rocque WJ, Porter DJ, Barnes JA, et al. Replication-associated activities of purified human papillomavirus type 11 E1 helicase. Protein Expr Purif 2000; 18: 148-59.
142. Titolo S, Pelletier A, Pulichino AM, et al. Identification of domains of VOL. 49, 2005 HPV E1 ATPase INHIBITORS 4841the human papillomavirus type 11 E1 helicase involved in oligomerization and binding to the viral origin. J Virol 2000; 74: 7349-61.
143. Faucher AM, White PW, Brochu C, Grand-Maître C, Rancourt J, Fazal G. Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase. J Med Chem 2004; 47: 18-21.
144. White PW, Faucher AM, Massariol MJ, et al. Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother 2005; 49: 4834-42.
145. Wang Y, Coulombe R, Cameron DR, et al. Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J Biol Chem 2004; 279: 6976-85.
146. Lu X, Zhang Y, Chen S, et al. Molecular Dynamics Simulation Study on the Mechanism of the Inhibition of ATP Hydrolysis with Inhibitors in Human Papillomavirus Type 18 E1 Helicase. ICCNCE 2013 2013; 30: 44-7.
147. Terenzi F, Saikia P, Sen GC, et al. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J 2008; 27: 3311-21.
148. Saikia P, Fensterl V, Sen GC. The Inhibitory Action of P56 on Select Functions of E1 Mediates Interferon's Effect on Human Papillomavirus DNA Replication. J Virol 2010; 84: 13036-9.
149. Lehoux M, Fradet-Turcotte A, Lussier-Price M, Omichinski JG, Archambault J. Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-binding peptide. J Virol 2012; 86: 3486-500.
150. Mohr IJ, Clark R, Sun S, Androphy EJ, MacPherson P, Botchan MR. Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science 1990; 250: 1694-9.
151. Frattini MG, Laimins LA. Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proc Natl Acad Sci USA 1994; 91: 12398-402.
152. Berg M, Stenlund A. Functional interactions between papillomavirus E1 and E2 proteins. J Virol 1997; 71: 3853-63.
153. Yoakim C, Ogilvie WW, Goudreau N, et al. Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex. Bioorg Med Chem Lett 2003; 13: 2539-41.
154. White PW, Titolo S, Brault K, et al. Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction. J Biol Chem 2003; 278: 26765-72.
155. Guardado-Mendoza R, Prioletta A, Jiménez-Ceja LM, et al. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch Med Sci 2013; 9: 936-43.
156. Wang Y, Coulombe R, Cameron DR, et al. Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J Biol Chem 2004; 279: 6976-85.
157. Fradet-Turcotte A, Archambault J. Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther 2007; 12: 431-51.
158. McPhillips MG, Ozato K, McBride AA. Interaction of bovine papillomavirus E2 protein with Brd4 stabilizes its association with chromatin. J Virol 2005; 79: 8920-32.
159. Wang X, Helfer CM, Pancholi N, Bradner JE, You J. Recruitment of Brd4 to the Human Papillomavirus Type 16 DNA Replication Complex Is Essential for Replication of Viral DNA. J Virol 2013; 87: 3871-84.
160. Sakakibara N, Chen D, Jang MK, et al. Brd4 Is Displaced from HPV Replication Factories as They Expand and Amplify Viral DNA. PLoS Pathog 2013; 9: e1003777.
161. Liu Y, Liu Z, Androphy E, Chen J, Baleja JD. Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry 2004; 43: 7421-31.
162. Baleja JD, Cherry JJ, Liu Z, et al. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 2006; 72: 49-59.
163. Kim MS, Bak Y, Park YS, et al. Wogonin induces apoptosis by suppressing E6 and E7 expressions and activating intrinsic signaling pathways in HPV-16 cervical cancer cells. Cell Biol Toxicol 2013; 29: 259-72.
164. Kim JE, Lee JI, Jin DH, et al. Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2. Oncol Rep 2014; 31: 2429-37.
165. He G, Wang Q, Zhou Y, et al. YY1 is a novel potential therapeutic target for treatment of HPV-infection induced cervical cancer by arsenic trioxide. Int J Gynecol Cancer 2011; 21: 1097-1104.
166. Sangthong S, Sangphech N, Palaga T, et al. Anthracene-9, 10-dione derivatives induced apoptosis in human cervical cancer cell line (CaSki) by interfering with HPV E6 expression. Eur J Med Chem 2014; 77: 334-42.
167. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006; 11: 813-25.
168. Kim DH, Jarvis RM, Xu Y, et al. Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. Analyst 2010; 135: 1235-44.
169. Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13: 59-67.
170. Choudhury AD, Choudhury MD, Chetia P, Chowdhury A, Talukdar AD. An in silico appraisal of azoic and disulphide derivatives for anticancer activity against HPV E6 oncoprotein to medicate cervical cancer. Comb Chem High Throughput Screen 2014; 17: 38-46.
171. Accardi L, Paolini F, Mandarino A, et al. A. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer 2014; 134: 2742-7.
172. Watts JK, Corey DR. Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic. The Journal of pathology 2012; 226: 365-79.
173. Sima N, Wang S, Wang W, et al. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 2007; 106: 299-304.
174. Reschner A, Bontems S, Le Gac S, et al. Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53. Gene Ther 2013; 20: 435-43.
175. Yamayoshi A, Kato K, Suga S, et al. Specific apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation. Oligonucleotides 2007; 17: 66-79.
176. Niu XY, Peng ZL, Duan WQ, Wang H, Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006; 16: 743-751.
177. Salazar-León J, Reyes-Román F, Meneses-Acosta A, et al. Silencing of HPV16 E6 and E7 oncogenic activities by small interference RNA induces autophagy and apoptosis in human cervical cancer cells. J Nucleic Acids Investig 2011; 2: 59-69.
178. Hillemanns P, Jentschke M, Evans TG, Soergel P, Hass R. Detection of E6-AP as a potential therapeutic target in cervical specimen of HPV-infected women. Arch Gynecol Obstet 2014; 289: 1281-6.
179. Chang JT, Kuo TF, Chen YJ, et al. Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers. Cancer Gene Ther 2010; 17: 827-836.
180. Wu SY, Singhania A, Burgess M, et al. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Ther 2011; 18: 14-22.
181. Gu W, Payne E, Sun S, Burgess M, McMillan NA. Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene Ther 2011; 18: 219-27.
182. Yang J, Li S, Guo F, Zhang W, Wang Y, Pan Y. Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes incervical cancer cells. Mol Med Rep 2013; 7: 998-1002.
183. Xiong Z, Dong X, Sun P, Zhang Y. Dose-effect research using nanopatch to deliver siRNA in the inhibition of HPV gene expression. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2013; 30: 1283-9.
184. Zhou J, Li B, Peng C, et al. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes. Antiviral Res 2013; 98: 305-13.
185. Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 2008; 111: 356-64.
186. Liu WL, Green N, Seymour LW, Stevenson M. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. Cancer Gene Therapy 2009; 75: 764-75.
187. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. Induction of apoptosis in human papillomavirus positive cancer cells by peptide aptamers targeting the viral E6 onco protein. Proc Natl Acad Sci USA 2000; 97: 6693-7.
188. Zhou J, Li B, Peng C, et al. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes. Antiviral Res 2013; 98: 305-13.
189. Putral LN, Bywater MJ, Gu W, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 2005; 68: 1311-19.
190. Jung HS, Erkin OC, Kwon MJ, et al. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int J Cancer. 2012; 130: 1925-36.
191. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 2001; 98: 1218-23.
192. Tan S, Hougardy BM, Meersma GJ, et al. Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptormediated apoptosis in human cervical carcinoma cells. Mol Pharmacol 2012; 81: 701-9.
193. Li X, Li Y, Hu J, et al. Plasmid-based E6-specific siRNA and coexpression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo. Cancer Lett 2013; 335: 242-50.
194. Li W and Anderson RA. Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16. Oncogene 2014; 33: 928-32.
195. Koivusalo R, Krausz E, Helenius H, Hietanen S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: Opposite effect of siRNA in combination with different drugs. Mol Pharmacol 2005; 68: 372-82.
196. Lappalainen K, Pirila L, Jaaskelainen I, Syrjanen K, Syrjanen S. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Anticancer Res 1996; 16: 2485-92.
197. Fiedler M, Muller-Holzner E, Viertler HP, et al. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J 2004; 18: 1120-22.
198. Oh KJ, Kalinina A, Park NH, Bagchi S. Deregulation of eIF4E: 4EBP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein. J Virol 2006; 80: 7079-88.
199. Reinstein E, Scheffner M, Oren M, Ciechanover A, Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the Nterminal residue. Oncogene 2000; 19: 5944-50.
200. Kanduc D. Translational regulation of human papillomavirus type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit alpha(1)-globin and human cytokeratin 7. J Virol 2002; 76: 7040-48.
201. Guo CP, Liu KW, Luo HB, et al. Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway. PLoS One 2011; 6: e17734.
202. Tan S, de Vries EG, van der Zee AG, de Jong S. Anticancer drugs aimed at e6 and e7 activity in hpv-positive cervical cancer. Curr Cancer Drug Targets 2012; 12: 170-184.
203. Southern SA, Herrington CS. Disruption of cell cycle control by human papillomavirus with special reference to cervical carcinoma. Int J Gynecol Cancer 2000; 10: 263-74.
204. Tewari KS, Taylor JA, Liao SY, et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a se vere combined immonodeficiency murinehuman xenograft model. Gyn Onco 2000; 77: 137-48.
205. Brehm A, Nielsen SJ, Miska EA, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999; 18: 2449-58.
206. Takai N, Kira N, Ishii T, Nishida M, Nasu K, Narahara H. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pac J Cancer Prev 2011; 12: 575-80.
207. Liu L, Yu X, Guo X, et al. Wang, miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep 2012; 5: 753-760.
208. Xu J, Li Y, Wang F, et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 2013; 32: 976-87.
209. Huang F, Lin C, Shi YH, Kuerban G. MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells. Asian Pac J Cancer Prev 2013; 14: 5915-20.
210. Yamamoto N, Kinoshita T, Nohata N, et al. Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma. Int J Oncol 2013; 43: 1855-63.
211. Wang XM, Xu J, Cheng ZQ, et al. Study on effects of microRNA-21 antisense oligonucleotide in vivo and in vitro on bionomics of human cervical squamous carcinoma cell lines SiHa. Zhonghua Bing Li Xue Za Zhi 2012; 41: 254-9.
212. Wang X, Wang HK, McCoy JP, et al. Oncogenic HPV infection interrupts the expression of tumorsuppressive miR-34a through viral oncoprotein E6. RNA 2009; 15: 637-47.
213. Li B, Hu Y, Ye F, Li Y, Lv W, Xie X. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer 2010; 20: 597-604.
214. Bommer GT, Gerin I, Feng Y. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-1307.
215. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumorsuppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci 2007; 104: 15472-77.
216. Pang RT, Leung CO, Ye TM, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010; 31: 1037-44.
217. Zhao S, Yao DS, Chen JY, Ding N. Aberrant expression of miR-20a and miR-203 in cervical cancer. Asian Pac J Cancer Prev 2013; 14: 2289-93.
218. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008; 27: 2575-82.
219. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008; 3: e2557.
220. Zhou X, Chen X, Hu L, et al. Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer, a casecontrol study in Chinese women. Gynecol Oncol 2010; 117: 287-90.
221. Li J, Ping Z, Ning H. MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer. Int J Mol Sci 2012; 13: 16053-64.
222. Chen Y, Ke G, Han D, Liang S, Yang G, Wu X. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res 2014; 320: 12-20.
223. Ke G, Liang L, Yang JM, et al. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the proapoptotic PRKCD gene. Oncogene 2013; 32: 3019-27.
224. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting MicroRNA. N Engl J Med 2013; 368: 1685-94.
225. Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120.